Article Sidebar
Published:
Jun 22, 2021Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Thieno [2, 3-d] pyrimidine inhibits gastric cancer cell proliferation via the down-regulation of bcl-2 and survivin expressions
Abstract
Purpose: To investigate the effect of thieno [2, 3-d] pyrimidine on gastric cancer (GC) cell proliferation, and elucidate the mechanism of action involved.
Methods: Human GC cells (MKN1, MKN28 and SGC 7901) were cultured in RPMI-1640 medium supplemented with 10 % fetal bovine serum (FBS) and 1 % penicillin/ streptomycin solution at 37 °C for 24 h in a humidified atmosphere of 5 % CO2 and 95 % air. After attaining 60 - 70 % confluency, the cells were treated with serum-free medium and graded concentrations of thieno [2, 3-d] pyrimidine (0 – 12 µM) for 24 h. Normal cell culture without thieno [2, 3-d] pyrimidine served as control group. The cells were used in logarithmic growth phase. Cell viability and apoptosis were assessed using 3 (4,5 dimethyl thiazol 2 yl) 2,5 diphenyl 2H tetrazolium bromide (MTT), and flow cytometric assays, respectively. The levels of expression of ZNF139, B cell lymphoma 2 (bcl-2) and survivin in MKN1 cells and orthotopically transplanted mice were determined using Western blotting and real-time quantitative polymerase chain reaction (qRT-PCR).
Results: Treatment of MKN1, MKN28 and SGC 7901 cells with thieno [2, 3-d] pyrimidine for 72 h led to significant and dose-dependent reductions in their viabilities, as well as significant and dose-dependent increases in the number of apoptotic cells (p < 0.05). The results of qRT-PCR and Western blotting showed that ZNF139 mRNA and protein expressions in MKN1 cells were significantly down-regulated by thieno [2, 3-d] pyrimidine treatment (p < 0.05). Thieno [2, 3-d] pyrimidine treatment significantly and dose-dependently down-regulated the expressions of bcl 2 and survivin proteins in MKN1 cells and orthotopically transplanted mice (p < 0.05). It also significantly and dose-dependently inhibited the proliferation of GC cells in orthotopic mouse model of GC after 31 days of treatment (p < 0.05).
Conclusion: These results suggest that thieno [2, 3-d] pyrimidine suppresses the proliferation of GC cells via down-regulation of the expressions of ZNF139, bcl 2 and sur¬vivin. Thus, it has potentials for development for the management of gastric cancer.
